Accueil>>Signaling Pathways>> Others>>SHIN1

SHIN1 (Synonyms: RZ2994)

Catalog No.GC32773

SHIN1 (RZ-2994) est un inhibiteur de la serine hydroxyméthyltransférase 1 et 2 humaine (SHMT1/2) avec des IC50 de 5 et 13 nM, respectivement, dans un test in vitro.

Products are for research use only. Not for human use. We do not sell to patients.

SHIN1 Chemical Structure

Cas No.: 2146095-85-2

Taille Prix Stock Qté
10mM (in 1mL DMSO)
233,00 $US
En stock
5mg
265,00 $US
En stock
10mg
448,00 $US
En stock
25mg
963,00 $US
En stock
50mg
1 620,00 $US
En stock
100mg
2 804,00 $US
En stock
1g
5 600,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 2 publications

Description Protocol Chemical Properties Product Documents Related Products

SHIN1 is a human serine hydroxymethyltransferse 1 and 2 (SHMT1/2) inhibitor with IC50s of 5 and 13 nM, respectively, in an in vitro assay.

SHIN1 inhibits human SHIN1 SHMT1/2 with IC50s of 5 and 13 nM, respectively in an in vitro assay. SHIN1 inhibits the growth of SHMT2 deletion HCT-116 cells with an IC50 of 10 nM. SHIN1 inhibits SHMT1/2 in HCT-116 cells. SHIN1 is particularly active against B-cell malignancies. SHIN1 blocks cell growth through a progressive depletion of purines, leading to loss of nucleotide triphosphates[1].

[1]. Ducker GS, et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11404-11409.

Avis

Review for SHIN1

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SHIN1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.